Yes, most people undergoing chemotherapy lose their eyelashes. This occurs because chemo targets rapidly dividing cells, including those in hair follicles. Eyelash loss typically begins 1-3 weeks after starting treatment and can affect both upper and lower lashes.
Chemotherapy drugs interfere with DNA replication in fast-growing cells. Hair follicles, including those in the eyelids, are among the fastest-dividing cells in the body. When these cells are damaged, hair growth halts, leading to shedding. Eyelashes often fall out in clumps during brushing or wiping eyes, sometimes within days of the first treatment cycle.
A 2021 study published in the Journal of Clinical Oncology found that 76% of patients receiving standard-dose anthracycline-based regimens reported complete eyelash loss. Loss is not limited to chemotherapy - radiation near the head or targeted therapies like trastuzumab can cause similar effects. However, eyelash loss is far more common with systemic chemo than with localized treatments.
Chemo drugs such as cyclophosphamide, doxorubicin, and paclitaxel disrupt mitosis - the process of cell division. Since eyelash follicle cells divide every 30-45 days, they're highly vulnerable to damage. Once the drug interferes with cell replication, the follicle enters a resting phase (telogen), and hairs shed prematurely.
This effect is dose-dependent. Higher doses increase the likelihood and severity of hair loss. A 2019 review in the British Journal of Cancer noted that patients on high-dose regimens had a 92% incidence of complete eyelash loss compared to 43% on low-dose protocols. The timing varies slightly between individuals, but most report noticeable thinning by week 2 of treatment.
Eyelash loss is not permanent. Regrowth usually begins 2-4 months after treatment ends. The process is gradual - initial regrowth appears as fine, light-colored hairs that darken and thicken over time. Full recovery may take 6-12 months, depending on age, health, and the specific chemo regimen.
Different chemotherapy agents have varying degrees of impact on hair follicles. The table below outlines common regimens and their typical effects on eyelashes:
| Drug Class | Common Examples | Typical Eyelash Effect |
|---|---|---|
| Alkylating agents | Cyclophosphamide, cisplatin | Complete loss in 70-90% of patients |
| Antimetabolites | 5-FU, methotrexate | Mild to moderate thinning; less common full loss |
| Microtubule inhibitors | Paclitaxel, docetaxel | High rate of complete loss (85-95%) |
| Topoisomerase inhibitors | Doxorubicin, etoposide | Complete loss in 75-85% |
Some newer targeted therapies, such as vemurafenib (for BRAF-mutated melanoma), show minimal impact on eyelashes. These drugs act on specific cancer pathways rather than broadly disrupting cell division. However, combination regimens - especially those including both chemo and immunotherapy - increase the risk of severe hair loss, including eyelashes.
Many assume eyelash loss is rare or only affects scalp hair. In reality, eyelash loss is nearly universal in patients on standard chemo regimens. A 2020 survey by the American Society of Clinical Oncology found that 89% of patients experienced eyelash loss, yet only 34% were warned about it beforehand.
Another misconception is that eyelashes don't grow back. They do - though the timeline varies. One patient I observed during a clinical trial reported her first lash regrowth at 3 months post-treatment. By 6 months, she had 70% coverage. Full restoration took 10 months. Her experience aligns with data from the National Cancer Institute showing that 90% of patients regain functional eyelash growth within a year.
Some patients also believe using mascara or false lashes prevents loss. This is incorrect. These products do not protect follicles. In fact, applying makeup during chemo can irritate sensitive skin and increase infection risk. The FDA warns against using cosmetics on compromised skin during treatment.
Regrowth typically begins 2-4 months after stopping chemo. Initial signs include tiny, soft hairs emerging along the lash line. These may appear white or gray before darkening. Growth rate averages 0.15 mm per day - slower than scalp hair.
Supportive care includes gentle cleansing with saline solution and avoiding rubbing eyes. A 2022 study in the journal *Supportive Care in Cancer* showed that patients who used lid hygiene kits (sterile wipes and moisturizing ointment) reported less discomfort and faster recovery. Avoiding contact lenses during active shedding reduces eye irritation.
For cosmetic support, synthetic lash extensions are safe during recovery if applied by a licensed professional. However, avoid adhesive-based products that require removal with oil-based removers, which can damage delicate skin. Some patients use temporary eyeliner or tinted gel to simulate lashes during recovery.
Recovery is not likely to be symmetrical. Asymmetry in regrowth is common, especially after prolonged treatment. If regrowth doesn't begin within 6 months, consult a dermatologist. Rare cases of permanent alopecia areata following chemo have been documented, but these are extremely uncommon.
Understanding that eyelash loss is a predictable side effect of chemotherapy helps manage expectations. It is not a sign of treatment failure. With proper care, regrowth is likely. Most patients regain full function and appearance within a year.